Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

BACKGROUND: Darbepoetin alfa (DA-α) is a long-acting erythropoiesis-stimulating glycoprotein which has half-life three-fold longer than that of Erythropoietin alfa (EPO). The objective of this study was to compare the efficacy and safety of DA-α injection versus EPO for treating renal anemia amongst...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Shubhadeep D., Bandi, Vamsi Krishna, Bheemareddy, Bala Reddy, Thakur, Pankaj, Chary, Sreenivasa, Mehta, Kalpana, Pinnamareddy, Vikranth Reddy, Pandey, Rajendra, Sreepada, Subhramanyam, Durugkar, Santosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417108/
https://www.ncbi.nlm.nih.gov/pubmed/30866856
http://dx.doi.org/10.1186/s12882-019-1209-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417108/
https://www.ncbi.nlm.nih.gov/pubmed/30866856
http://dx.doi.org/10.1186/s12882-019-1209-1

Ejemplares similares